Impedance-based assay for pan-cancer early and rapid detection of cell-free DNA
Dube, T.; Prasad, P.; Swami, P.; Singh, A.; Verma, M.; Tanwar, P.; Chowdhury, S.; Gupta, S.
Show abstract
Aberrant DNA methylation is a hallmark of cancer, and plasma cell-free DNA (cfDNA) containing these abnormal methylation patterns has emerged as a promising non-invasive biomarker for pan-cancer detection. However, intrinsic challenges remain that continue to limit its broad clinical application. Here we show a simple and rapid impedance biosensor called Asima Rev that can detect cancer cfDNA in under 5 min without the need for any molecular labelling, electrode modification, signal amplification, or target enrichment steps. Using 216 clinical samples (50 healthy) from 15 different cancer types (all stages) we show an overall sensitivity and specificity of 96.4% and 94.0%, respectively. Differences in methylation content between cancerous and healthy cfDNA lead to distinct solvation behaviour and electro-physicochemical property that remain consistent across cancer types regardless of the distribution patterns of methyl cytosine. Our test exploits this inherent difference.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Genetic Circuits Combined with Machine Learning Provides Fast Responding Living Sensors 96%
- Affordable plasmonic biosensing: democratizing SERS with scalable, field-compatible substrate fabrication 96%
- Synthetic Nanobody-Functionalized Nanoparticles for Accelerated Development of Rapid, Accessible Detection of Viral Antigens 95%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.